Amsterdam UMC Imaging Center, comprising Tracer Center Amsterdam (former VUmc Imaging Center Amsterdam)Amsterdam UMC Imaging Center


Prof. dr Guus van Dongen
De Boelelaan 1117, 1081 HV Amsterdam
Amsterdam UMC

The imaging center comprises: In the basement: Cyclotron BV, a company that supplies medical isotopes and tracers to Dutch hospitals and abroad. Ground floor: clinical nuclear medicine with PET-CT, PET-MRI and SPECT-CT. Floor 1: clinical high throughput radiology with dexa, rontgen, mammography and ultra sound. Floor 2: clinical radiology with MRIs and CTs. Floor 3: Tracer Center Amsterdam, an R&D facility for tracer development. Floor 4: LaserLab Amsterdam.

A main research topic of the Tracer Center Amsterdam is “imaging in drug development and application”, which should find solutions for the problem of “expensive” drugs. Expertise ranges from radionuclide production, through new tracer development and preclinical evaluation, to clinical use of new and existing tracers with highly qualified specialists who operate in a truly multidisciplinary environment. The whole process is performed according to state of-the-art GMP/GLP/GCP standards. In addition, the GMP facilities are inspected on a regular basis by the Dutch Health Care Inspectorate and are licensed to manufacture
tracers for human use according to the latest EU guidelines. Moreover, the Imaging Center possesses PET data analysis and training centers. Together with LaserLab Amsterdam also optical tracers are developed.

The Amsterdam UMC Imaging Center will propel research and public-private interactions in translational high-end molecular imaging and tracer development, an area in which the Netherlands (academia, SMEs as well as large industry) is internationally recognized. Breakthroughs are expected in the form of better understanding of high impact diseases and disease-specific molecular targets, more efficient development and use of diagnostics and (expensive) targeted therapy/drugs, and better understanding of inter-patient
variability. These achievements will result in reduced costs of drug development, while bringing better quality of life for patients and a reduction in healthcare costs. The infrastructure will be attractive and have open access for third party users (“on-shoring” of international R&D activities, and creating opportunities for open innovation).

The Amsterdam UMC Imaging Center (± 15.000 m2 ) will comprise 3 x 18 MeV cyclotrons and an oxygencyclotron for PET radionuclide production and GMP facilities for large scale production of PET tracers that are routinely used in the Dutch clinical hospitals. The Tracer Center Amsterdam (± 2.500 m2 ) being the R&D environment of the Imaging Center comprises GMP labs with 12 hot cells, 5 research hot cells, 14 fume hoods; extensive facilities for (radio)chemistry, pharmacology, metabolite analysis, biology and animal facilities; preclinical PET/CT, PET/MRI and Optical Scanners; LC-MS/MS and an array of other analytical equipment. For clinical purposes, the following equipment is available: 1 x PET-MRI (3T): 2 x PET-CT; 1 x SPECT-CT; 1 x Gamma Camera; 3 x CT (64, 128 en 256 MDCT); 4 x MRI (2 x 1,5 T en 2 x 3T); 2 x Angio-intervention units; 7 x Echo-units; 1 X Mammograph; 1 x DXA; 6 x Conventional röntgen unit; several mobile röntgen units for operation theater.

Aansluiting bij strategische ontwikkelingen
Life Sciences & Health
Personalised medicine: uitgaan van het individu
Gezondheidszorgonderzoek, preventie en behandeling
Meten en detecteren: altijd, alles en overal